Lyka Labs Ltd
Thu 13/03/2025,15:48:4 | NSE : LYKALABS
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 101.79
Previous Close
₹ 100.35
Volume
164395
Mkt Cap ( Rs. Cr)
₹354.51
High
₹ 103.78
Low
₹ 98.00
52 Week High
₹ 176.59
52 Week Low
₹ 97.90
Book Value Per Share
₹ 27.71
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Lyka Labs Ltd
Your Vote -
Buy
57.14%
Hold
28.57%
Sell
14.29%
57.14%
14 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
100%
Sell Order Quantity
0%
Bid Price
Qty
121.65
1000
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
1000
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Lyka Labs Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Lyka Labs - Shareholders meeting
-
Lyka Labs - Shareholders meeting
-
Lyka Labs - Shareholders meeting
-
Lyka Labs - Shareholders meeting
-
Lyka Labs - Voting Results Of The Meeting Of The Preference Shareholders Of The Company Convened On Tuesday, 4Th March 2025,
-
Lyka Labs - Voting Results Of The Meeting Of The Unsecured Creditors Of The Company Convened As Per The NCLT Order On Tuesday
-
Lyka Labs - Voting Results Of The Meeting Of The Secured Creditors Of The Company Convened As Per The NCLT Order On Tuesday,
-
Lyka Labs - Voting Results Of The Meeting Of The Equity Shareholders Of The Company For Court Convened Meeting Held On Tuesda
-
Lyka Labs - Shareholders meeting
-
Lyka Labs - Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting
-
Lyka Labs - Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements)\r\nRegulations, 2015\r\n\r\n Intimat
-
Lyka Labs - Action(s) initiated or orders passed
-
Lyka Labs - General Updates
-
Lyka Labs - Credit Rating Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regula
-
Lyka Labs - Notice Of Shareholders Meetings-XBRL
-
Lyka Labs - Copy of Newspaper Publication
-
Lyka Labs - Integrated Filing- Financial
-
Lyka Labs - Integrated Filing (Financial)
-
Lyka Labs - Financial Result Updates
-
Lyka Labs - Outcome of Board Meeting
-
Lyka Labs Q3 net profit jumps 98.53% at Rs 2.70 cr
-
Lyka Labs - Intimation Under Regulations 30 And 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations,
-
Lyka Labs - Board Meeting Outcome for Outcome Of The Board Meeting - 4Th March, 2025
-
Lyka Labs - Copy of Newspaper Publication
-
Lyka Labs - Shareholders meeting
-
Lyka Labs - Notice Of Meeting Of Secured Creditors Pursuant To The Order Of Hon'Ble National Company Law Tribunal Division Be
-
Lyka Labs - Notice Of Meeting Of Secured Creditors Pursuant To The Order Of Hon'Ble National Company Law Tribunal Division Be
-
Lyka Labs - Notice Of Meeting Of Unsecured Creditors Pursuant To The Order Of Hon'Ble National Company Law Tribunal Division
-
Lyka Labs - Shareholders meeting
-
Lyka Labs - Shareholders meeting
-
Lyka Labs - Shareholders meeting
-
Lyka Labs - Shareholders meeting
-
Lyka Labs - Notice Of Meeting Of Preference Shareholders Pursuant To The Order Of Hon'Ble National Company Law Tribunal Divis
-
Lyka Labs - Notice Of Meeting Of Equity Shareholders Pursuant To The Order Of Hon'Ble National Company Law Tribunal Division
-
Lyka Labs - Intimation Of Dispatch Of Notices For Shareholders' And Creditors' Meetings Pursuant To The Order Of Hon'Ble Nati
-
Lyka Labs - Updates
-
Lyka Labs - Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Update On The Scheme Of Amalgamation
-
Lyka Labs has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024
-
Lyka Labs - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Lyka Labs - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Lyka Labs - Updates
-
Lyka Labs - Change Of Name Of Registrar And Share Transfer Agent (\RTA\) Of The Company
-
Lyka Labs - Board Meeting Intimation
-
Lyka Labs - Board Meeting Intimation for To Consider And Approve The Unaudited Standalone And Consolidated Financial Results
-
Lyka Labs - Trading Window-XBRL
-
Lyka Labs - Trading Window
-
Lyka Labs gets CDSCO nod to manufacture & market Tofacitinib Ointment
Key fundamentals
Evaluate the intrinsic value of Lyka Labs Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 155.8986 | 147.4678 | 172.6534 | 165.5541 | 155.0602 |
Liabilities | 155.8986 | 147.4678 | 172.6534 | 165.5541 | 155.0602 |
Equity | 33.09 | 30.69 | 28.69 | 28.69 | 28.69 |
Gross Profit | 14.5604 | 15.6005 | 97.4991 | 14.4256 | -3.2152 |
Net Profit | -2.2689 | -13.2866 | 39.9023 | -14.4589 | -55.3865 |
Cash From Operating Activities | 3.0895 | 6.8748 | 76.5342 | 5.7503 | -11.4484 |
NPM(%) | -2.13 | -16.48 | 24.27 | -23.22 | -135.93 |
Revenue | 106.3963 | 80.5926 | 164.3488 | 62.263 | 40.7434 |
Expenses | 91.8359 | 64.9921 | 66.8497 | 47.8374 | 43.9586 |
ROE(%) | -2.29 | -13.43 | 40.34 | -14.61 | -55.99 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|
Peers
Other companies within the same industry or sector that are comparable to Lyka Labs Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 808.20 | -1.14 | 11.41 | 56.70 | 1321.50 | 1.42 |
Lotus Eye Hospital and Institute Ltd | 57.06 | -0.77 | 237.75 | 206.61 | 14.01 | 0.88 |
Vaishali Pharma Ltd | 12.12 | -5.90 | 606.00 | 106.50 | 2.31 | 0.00 |
Astec Lifesciences Ltd | 653.90 | -5.55 | 0.00 | 194.82 | -239.30 | 0.00 |
Company Info
YEAR EVENTS 1976 - The company was incorporated on 29th December as a private Limited Company and Converted into a Public Limited company on 19th December, 1985. - The company alongwith Gujarat Industrial Investment Corporation Limited promoted a new company, Gujarat Lyka Organics Limited, at Ankleshwar in Gujarat for the manufacture of Semi-Synthetic Penicilline. 1993 - The Company proposed to offer 20,60,000 No. of Equity Shares of Rs. 10/- each at an issue price not exceeding Rs. 35/- per share on the basis of one Equity Share for every two Equity Shares. 1994 - The company is negtiating tieup arrangements with internationally reputed manufactureres for marketing and manufacturing its products in India. 1995 - Government of India has selected the Company for the award of the Certificate of Merit for the excellent export performance during 1993-94. Further CHEMEXCIL has also selected the Company for the SECOND AWARD for outstanding export performance during 1993-94. - The Company has commenced production at its new formulation plant at Tarapur, have been designed with state-of-the-art technology to meet with the International Standards of Good Manufacturing Practices and with Total Quality Management Systems (TOM). - The Company has also set up additional manufacturing facility for ointment at Ankleshwar - Lyka Exports Limited became a subsidiary of the Company. - The Company allotted 1,50,000 Equity Shares to Foreign Institutional Investors on private placement basis and 40,000 Equity Shares to the Promoters. 1997 - The Company during the period has allotted 5,65,000 Secured Redeemable Non-Convertible Debentures of Rs.100/- each aggregating to Rs.5.65 crores. - Lyka Labs Limited has entered into the marketing of skin cream which is used to treat dry skin conditions. - The company has recently launched a rubefacient, too. 1998 - The Company's Administrative Office and Corporate Quality Assurance at Mumbai and Plant at Tarapur has been awarded ISO 9002 Certification for its Quality Management System by SGS Yarsley International Certification Services Limited, U.K. 1999 - Lyka Labs has launched a product-rationalisation exercise to exit cardiovasculars which is a non-focus area, sources opine. - The company recently launched dermatological skin ointment Cetraben. 2000 - The Company to issue on preferential basis 30,00,000 No. of equity shares of Rs. 10/- each on preferential allotment to Financial Institutions/FIIs/MFs. 2003 -Entered into an agreement with BDR Pharmaceuticals International to form a 50:50 joint venture. The new company will be focussed on enhancing Lyka's export business to developed and developing countries, which at present being handled by Lyka. -Lyka Labs marketing tie-up with Bio X-Healthcare -Lyka Labs Ltd has informed that the Company has decided to dis-invest its holding in its subsidary, Lyka Exports Ltd. In view of this, Lyka Exports Ltd. will cease to be its subsidary. 2005 -Lyka Labs launches BIOXTRA Toothpaste & Gel -Clearwater Capital Partners Limited joined hands with Lyka Labs Ltd 2006 -Lyka Labs Ltd has informed that Lyka Labs Ltd has changed the Registrar and Transfer Agent from MCS Ltd to Sharex Dynamic ( India ) Limited, Unit No.1, Luthra Ind. Premises, Andheri Kurla Road, Safed Pool, Andheri ( East ) Mumbai 400 072, Tel No. 2851 5606/44 Fax 2851 2885, with effect from September 30, 2006. 2008 -Lyka Labs Ltd has appointed Mr. D G Shah as Additional Director of the Company. 2009 - Lyka Labs Ltd has re-appointed Shri. N. I. Gandhi as Managing Director of the Company w.e.f. 1st April, 2009, subject to approval of the Central Government. 2010 - Lyka Labs Ltd has appointed Mr. Manish Jaywant as CFO w.e.f. June 01, 2010. 2011 - The Company has been conferred Certificate of Appreciation Patent Award by Pharmaceuticals Export Promotion Council. - The Company has entered MOU with European based Company for Transfer Known- How / Technology to manufacture lyophilized product. 2012 - Email ID : investorredressal@lykalabs.com 2014 -Mr. Yogesh B. Shah has been appointed as Chief Finance Officer. 2016 -Lyka Healthcare Limited, an entirely owned subsidiary of Lyka Labs Limited, has launched two domestic marketing divisions. 2017 -Amalgamation of Lyka Healthcare Ltd. (Transferor Company) being the wholly owned subsidiary with Lyka Labs Ltd. (Transferee Company). 2021 -"Merger of Lyka Exports Limited with Lyka Labs Limited".
YEAR EVENTS 1976 - The company was incorporated on 29th December as a private Limited Company and Converted into a Public Limited company on 19th December, 1985. - The company alongwith Gujarat Industrial Investment Corporation Limited promoted a new company, Gujarat Lyka Organics Limited, at Ankleshwar in Gujarat for the manufacture of Semi-Synthetic Penicilline. 1993 - The Company proposed to offer 20,60,000 No. of Equity Shares of Rs. 10/- each at an issue price not exceeding Rs. 35/- per share on the basis of one Equity Share for every two Equity Shares. 1994 - The company is negtiating tieup arrangements with internationally reputed manufactureres for marketing and manufacturing its products in India. 1995 - Government of India has selected the Company for the award of the Certificate of Merit for the excellent export performance during 1993-94. Further CHEMEXCIL has also selected the Company for the SECOND AWARD for outstanding export performance during 1993-94. - The Company has commenced production at its new formulation plant at Tarapur, have been designed with state-of-the-art technology to meet with the International Standards of Good Manufacturing Practices and with Total Quality Management Systems (TOM). - The Company has also set up additional manufacturing facility for ointment at Ankleshwar - Lyka Exports Limited became a subsidiary of the Company. - The Company allotted 1,50,000 Equity Shares to Foreign Institutional Investors on private placement basis and 40,000 Equity Shares to the Promoters. 1997 - The Company during the period has allotted 5,65,000 Secured Redeemable Non-Convertible Debentures of Rs.100/- each aggregating to Rs.5.65 crores. - Lyka Labs Limited has entered into the marketing of skin cream which is used to treat dry skin conditions. - The company has recently launched a rubefacient, too. 1998 - The Company's Administrative Office and Corporate Quality Assurance at Mumbai and Plant at Tarapur has been awarded ISO 9002 Certification for its Quality Management System by SGS Yarsley International Certification Services Limited, U.K. 1999 - Lyka Labs has launched a product-rationalisation exercise to exit cardiovasculars which is a non-focus area, sources opine. - The company recently launched dermatological skin ointment Cetraben. 2000 - The Company to issue on preferential basis 30,00,000 No. of equity shares of Rs. 10/- each on preferential allotment to Financial Institutions/FIIs/MFs. 2003 -Entered into an agreement with BDR Pharmaceuticals International to form a 50:50 joint venture. The new company will be focussed on enhancing Lyka's export business to developed and developing countries, which at present being handled by Lyka. -Lyka Labs marketing tie-up with Bio X-Healthcare -Lyka Labs Ltd has informed that the Company has decided to dis-invest its holding in its subsidary, Lyka Exports Ltd. In view of this, Lyka Exports Ltd. will cease to be its subsidary. 2005 -Lyka Labs launches BIOXTRA Toothpaste & Gel -Clearwater Capital Partners Limited joined hands with Lyka Labs Ltd 2006 -Lyka Labs Ltd has informed that Lyka Labs Ltd has changed the Registrar and Transfer Agent from MCS Ltd to Sharex Dynamic ( India ) Limited, Unit No.1, Luthra Ind. Premises, Andheri Kurla Road, Safed Pool, Andheri ( East ) Mumbai 400 072, Tel No. 2851 5606/44 Fax 2851 2885, with effect from September 30, 2006. 2008 -Lyka Labs Ltd has appointed Mr. D G Shah as Additional Director of the Company. 2009 - Lyka Labs Ltd has re-appointed Shri. N. I. Gandhi as Managing Director of the Company w.e.f. 1st April, 2009, subject to approval of the Central Government. 2010 - Lyka Labs Ltd has appointed Mr. Manish Jaywant as CFO w.e.f. June 01, 2010. 2011 - The Company has been conferred Certificate of Appreciation Patent Award by Pharmaceuticals Export Promotion Council. - The Company has entered MOU with European based Company for Transfer Known- How / Technology to manufacture lyophilized product. 2012 - Email ID : investorredressal@lykalabs.com 2014 -Mr. Yogesh B. Shah has been appointed as Chief Finance Officer. 2016 -Lyka Healthcare Limited, an entirely owned subsidiary of Lyka Labs Limited, has launched two domestic marketing divisions. 2017 -Amalgamation of Lyka Healthcare Ltd. (Transferor Company) being the wholly owned subsidiary with Lyka Labs Ltd. (Transferee Company). 2021 -"Merger of Lyka Exports Limited with Lyka Labs Limited".
Read More
Parent Organisation
Lyka Labs Ltd.
Founded
29/12/1976
Managing Director
Mr.Kunal Gandhi
NSE Symbol
LYKALABSEQ
FAQ
The current price of Lyka Labs Ltd is ₹ 99.33.
The 52-week high for Lyka Labs Ltd is ₹ 103.78 and the 52-week low is ₹ 98.00.
The market capitalization of Lyka Labs Ltd is currently ₹ 354.51. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Lyka Labs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Lyka Labs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Lyka Labs Ltd shares.
The CEO of Lyka Labs Ltd is Mr.Kunal Gandhi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.